Urinary Tract Infection Testing Market Size & Growth Forecast 2026–2035, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Urinary Tract Infection Testing Market size was estimated at USD 652.41 Million in 2025 and is projected to grow at a 4.6% CAGR from 2026 to 2035, attaining USD 1.02 Billion by 2035. The industry revenue for 2026 is calculated at USD 678.25 million.

• Base Year Value (2025): USD 652.41 Million
• CAGR (2026-2035): 4.6%
• Forecast Year Value (2035): USD 1.02 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Urinary Tract Infection Testing Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to strong diagnostic laboratory access, established clinical testing pathways, and high healthcare utilization for symptomatic urinary infections.
  • Asia Pacific growth at 5.24% CAGR is driven by expanding healthcare access, increasing patient entry into formal care systems, and improved availability of diagnostic testing services.

• Segment Momentum:

  • Cystitis accounted for 43.88% of the market in 2025, supported by high testing volumes from routine lower urinary tract infection diagnosis and consistent demand across everyday clinical workflows.
  • Urogynecologists are the fastest-growing end-use segment as more patients with recurrent or complex urinary conditions require specialized diagnostic evaluations and targeted testing approaches.

• Market Expansion Drivers:

  • Rising prevalence of recurrent urinary tract infections increasing diagnostic testing volumes among women populations.
  • Expanding adoption of point-of-care and at-home UTI testing kits improving accessibility and convenience.
  • Growing investment in smartphone-enabled rapid diagnostic technologies enhancing decentralized infection screening capabilities.

• Leading Market Participants:

  Major players in the urinary tract infection testing market include bioMérieux SA (France), Roche Holding AG (Switzerland), QIAGEN N.V. (Germany), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (United States), Abbott Laboratories (United States), Randox Laboratories Ltd. (United Kingdom), T2 Biosystems, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 652.41 Million
  • Projected Market Size: USD 1.02 Billion by 2035
  • Growth Forecasts: 4.6% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Cystitis (Type) | Reference Laboratories (End Use)
  • Emerging Opportunity Segment: Pyelonephritis (Type) | Urogynecologists (End Use)

Market Growth Drivers and Industry Trends

Rising prevalence of recurrent urinary tract infections increasing diagnostic testing volumes among women populations

Repeated UTI episodes among women are translating into more frequent urine screening, culture confirmation, and follow-up testing, directly increasing demand for the urinary tract infection testing market. Because recurrent infections often require clinicians to distinguish between reinfection, incomplete treatment response, and more complicated urinary conditions, testing becomes a routine part of care rather than a one-time diagnostic event. This pattern increases testing frequency per patient, supports stronger utilization of both rapid dipstick methods and laboratory-based diagnostics, and reinforces purchasing by primary care clinics, gynecology practices, urgent care centers, and diagnostic laboratories serving a high-volume female patient base.

Expanding adoption of point-of-care and at-home UTI testing kits improving accessibility and convenience

Greater use of point-of-care and at-home kits is reshaping how patients enter the diagnostic pathway, supporting market expansion by removing delays associated with clinic visits and centralized lab processing. In the urinary tract infection testing market, convenience matters because symptoms are often acute, uncomfortable, and time-sensitive, leading patients to favor faster initial screening options and providers to adopt tools that enable immediate triage. This shift increases testing penetration among individuals who might otherwise postpone evaluation, while also creating stronger demand for easy-to-use products that fit retail, pharmacy, telehealth, and urgent care distribution models.

Growing investment in smartphone-enabled rapid diagnostic technologies enhancing decentralized infection screening capabilities

Investment in smartphone-linked diagnostic platforms is strengthening market development by turning UTI screening into a more connected, decentralized process with clearer pathways for interpretation and follow-up. In the urinary tract infection testing market, these technologies improve practical usability by pairing rapid test results with app-based image capture, guided instructions, and data sharing that can support remote clinical review. That combination makes decentralized screening more credible for both consumers and care providers, encourages adoption outside traditional laboratory settings, and helps manufacturers differentiate offerings through digital integration rather than relying only on the chemistry of the test itself.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of recurrent urinary tract infections increasing diagnostic testing volumes among women populations	1.80%	Moderate	North America, Europe	High	Near Term
Expanding adoption of point-of-care and at-home UTI testing kits improving accessibility and convenience	1.50%	Moderate	North America, Asia Pacific	High	Mid Term
Growing investment in smartphone-enabled rapid diagnostic technologies enhancing decentralized infection screening capabilities	1.20%	Moderate	Asia Pacific, Europe	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the urinary tract infection testing market, supported by broad access to diagnostic laboratories, established clinical testing pathways, and high healthcare utilization for symptomatic infections. The region’s leadership is aided by routine physician-led diagnosis, quicker movement from consultation to urinalysis or urine culture, and stronger adoption of standardized testing protocols across hospitals, clinics, and outpatient settings. This practical integration of testing into everyday care sustains high testing volumes and keeps the region at the forefront of market activity.

Asia Pacific is projected to expand at a 5.24% CAGR over the forecast period, with growth in the urinary tract infection testing market being fueled by rising access to healthcare services and expanding diagnostic use across developing and urbanizing care systems. As more patients enter formal care channels for infection-related symptoms, demand is increasing for timely and accessible testing in both hospital and decentralized settings. The region’s growth momentum is also shaped by the broader expansion of diagnostic infrastructure, which is improving the availability of testing and supporting greater adoption in routine clinical practice.

Key Country Insights

United States

Rapid Diagnostic Integration

The U.S. is prioritizing rapid urinary tract infection testing that supports antimicrobial stewardship and improves diagnostic accuracy across hospitals, urgent care centers, and outpatient clinics. Demand is encouraging broader adoption of automated and molecular testing platforms for faster clinical decision-making.

Japan

Aging Care Diagnostics

Japan is expanding urinary tract infection testing to address the clinical needs of its aging population and long-term care facilities. Greater use of accurate diagnostic methods helps clinicians differentiate infections quickly while supporting appropriate treatment selection.

South Korea

Digital Laboratory Adoption

South Korea is integrating advanced urinary tract infection testing with digitally connected laboratory systems to improve turnaround times and diagnostic precision. Healthcare providers are adopting automated platforms that enhance workflow efficiency in both hospital and reference laboratory settings.

Germany

Laboratory Efficiency Focus

Germany emphasizes standardized laboratory workflows and reliable urine diagnostics to improve testing consistency and reduce unnecessary antibiotic use. Clinical laboratories are expanding automated testing solutions that strengthen diagnostic quality while supporting efficient healthcare delivery.

France

Antimicrobial Stewardship Support

France is strengthening urinary tract infection testing practices that align with antimicrobial stewardship initiatives and evidence-based prescribing. Clinical laboratories are adopting more accurate diagnostic technologies to reduce unnecessary antibiotic use and improve patient management.

Italy

Hospital Testing Modernization

Italy is modernizing urinary tract infection testing through investments in laboratory automation and standardized diagnostic protocols. Healthcare providers are improving access to reliable testing methods that support faster diagnosis and more targeted treatment decisions.

Segment Leadership and Growth Trends

  Type Segment Analysis: Cystitis (Largest Segment) vs Pyelonephritis (Fastest-Growing Segment)

Cystitis held the dominant position in the urinary tract infection testing market in 2025, accounting for a 43.88% share. its position is maintained through the high testing volume associated with routine lower urinary tract infection diagnosis, where patients commonly present with recognizable symptoms that prompt early clinical evaluation. This keeps cystitis central to day-to-day diagnostic workflows across care settings, supporting steady demand for standard urine-based testing and reinforcing its dominant share in the market.

Pyelonephritis is emerging as the fastest-growing segment in the urinary tract infection testing market because it is more closely tied to cases that require timely and accurate assessment to guide treatment decisions and prevent complications. Growth is being reinforced through the stronger clinical need for more definitive testing in suspected kidney-associated infections, where the consequences of delayed or imprecise diagnosis are greater than in less severe presentations. That practical requirement is helping pyelonephritis testing gain momentum faster than other infection types.

End Use Segment Analysis: Reference Laboratories (Largest Segment) vs Urogynecologists (Fastest-Growing Segment)

In 2025, reference laboratories represented the largest end-use segment in the urinary tract infection testing market with a 28.84% share. Their position reflects the operational advantage of handling large specimen volumes, performing standardized testing procedures, and supporting broad physician networks that rely on centralized diagnostic capacity. This model is well suited to urinary tract infection testing market demand, where consistency, processing efficiency, and access to confirmatory analysis help maintain the segment’s leading share.

Urogynecologists are the fastest-growing end-use segment in the urinary tract infection testing market as more specialized evaluation is being directed toward patients with recurrent, persistent, or clinically complex urinary conditions. Their growth is reinforced through the practical need for targeted diagnostic workups in patients whose symptoms overlap with broader pelvic and urinary disorders, making specialist-led testing more relevant than in routine cases. This expanding role in managing complex female urinary health issues is allowing urogynecologists to grow faster than other end-use categories.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Urethritis, Cystitis, Pyelonephritis	Cystitis	Pyelonephritis
End Use	General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Hospital Emergency Departments, Urgent Care, Others	Reference Laboratories	Urogynecologists

Competitive Landscape and Market Positioning

Prominent players in the urinary tract infection testing market:

1. bioMérieux SA (France)

2. Roche Holding AG (Switzerland)

3. QIAGEN N.V. (Germany)

4. Danaher Corporation (United States)

5. Thermo Fisher Scientific Inc. (United States)

6. Siemens Healthineers AG (Germany)

7. Becton Dickinson and Company (United States)

8. Abbott Laboratories (United States)

9. Randox Laboratories Ltd. (United Kingdom)

10. T2 Biosystems Inc. (United States)

Increasing demand for faster and more accurate infectious disease diagnosis is shaping developments in the urinary tract infection testing market. Companies are focusing on automated and rapid-testing platforms that minimize turnaround times while improving detection sensitivity. The growing use of point-of-care diagnostics and digital laboratory integration is also contributing to enhanced workflow efficiency and broader accessibility of testing solutions.

Industry Development/News

Company Name	Date	Key Development
Mankind Pharma	Sep-24	Mankind Pharma launched a self-test kit for the rapid detection of urinary tract infections. By enabling patients to identify leukocyte and nitrite markers at home, the product addresses the growing demand for convenient, private, and accessible diagnostic solutions, strengthening the company's competitive position within the consumer-focused diagnostic segment.
Thermo Fisher Scientific	Dec-22	Thermo Fisher Scientific launched TrueMark Infectious Disease Research Panels, a technology suite designed for the rapid and accurate detection of microorganisms associated with urinary, respiratory, and gastrointestinal conditions. This development enhances the company’s molecular diagnostic capabilities, providing high-precision tools for identifying pathogens and associated antimicrobial resistance markers in diverse clinical settings.
Sysmex Corporation	Sep-22	Sysmex Corporation introduced the UF-1500, a fully automated urine particle analyzer designed to optimize urine sediment testing. The platform improves laboratory efficiency and standardization in diagnostic workflows. This product launch represents a strategic effort to enhance high-throughput testing capabilities, providing clinical laboratories with a reliable automated solution for detecting infection markers in urine samples.
Vela Diagnostics	May-22	Vela Diagnostics launched the AMR PCR Test alongside the PathoKey MP UTI ID kit. These diagnostic solutions are specifically engineered to detect UTI-causing pathogens and screen for antimicrobial resistance genes. The integration of pathogen identification and resistance profiling provides clinicians with actionable data to inform antibiotic therapy, addressing a critical need for precision in infectious disease management.
BD (Becton, Dickinson and Company)	Dec-21	BD completed the acquisition of Scanwell Health Inc., a developer of smartphone-aided at-home medical test kits. This acquisition signifies a strategic move to integrate digital health technologies with diagnostic testing, expanding BD's footprint in the decentralized and at-home testing market, which is increasingly relevant for routine monitoring and screening of urinary tract infections.